Tag Archives: pharmaceutical

R&D at UCD

Posted on by
R&D

R&D

The preeminence of R&D at UCD is very much in evidence and globally renown. Despite the shortcomings of the current government and its recent track record on the economy, its long term investment  strategy in relation to R&D appears to be on target. €14.8m is being invested over the next five years in the Systems Biology Ireland Research Centre and will be centered at the UCD campus, already home to NIBRT, (National Institute for Bioprocessing Research and Training).

It is hoped that this will make Ireland a leader in the consolidation of computing, maths and biology and will further enhance Ireland’s attractiveness as a site of  foreign direct investment for the future as this state of the art computing center will considerably promote Ireland as a significant R&D center of expertise and scientific research in addition to being a major scientific contributor in the fight against cancer and various other life threatening medical conditions

Adding  to the attractiveness of  NIBRT’s direct industrial applications and capabilities potential, the consolidation of computer modeling and study of biological systems offers a similar appeal to R&D clients. Collectively these  will present considerable marketing advantages for Ireland as a center for foreign direct investment and offers enhanced potential  for collaborative projects which can only improve Ireland’s already excellent reputation for world class scientific and engineering professionalism. 

For more news on developments and employment opportunities in science and technolgy in Ireland, please visit our news and jobs pages

Champix conquers smoking addiction

Posted on by
Healthy option

Healthy option

For all you smokers out there, there is help after all in the shape of a tiny white pill called Champix manufactured by Pfizer.

Champix offers:

Reduced craving and withdrawal symptoms

Significantly greater quit success vs. NRT patch, bupropion or placebo at 12 weeks

Over 8.9 million patients’ experience worldwide

Champix works primarily in two ways. Firstly, it reduces the smoker’s craving for nicotine by binding to nicotine receptors in the brain and reduces the symptoms of withdrawal. Secondly, it reduces the satisfaction a smoker receives when smoking a cigarette.

The European Commission approved Champix on September 29th, 2006 as a “stop smoking” aid for adults, based on the results from clinical trials.

It should be noted that continued abstinence from cigarettes is higher (70% compared with 50%) when patients take the drug for 24 weeks as opposed to 12, so it may be appropriate for patients who have succeeded in quitting smoking at the 12 week point to take the drug for a further 12 weeks.

For all you smokers struggling to quit, this could be another option for you. Good luck and do let us know in Jackie Brown Medical how you get on.

One of our staff members is trying it out.  Click on the comment tab below to tell us about methods you found successful/unsuccessful.